title: UGT2B17 Genotype and the Pharmacokinetic Serum Profile of Testosterone during Substitution Therapy with Testosterone Undecanoate. A Retrospective Experience from 207 Men with Hypogonadism.
abstract: BACKGROUND
  Testosterone (T) is mainly excreted in the urine as testosterone glucuronide (TG). This glucuronidation is partly dependent on the UGT2B17 genotype, and TG excretion is therefore lower in men having the UGT2B17 deletion. However, the possible influence of UGT2B17 genotype on serum T during androgen therapy is unknown. We retrospectively investigated the possible association between the UGT2B17 gene polymorphism and serum T levels in hypogonadal men during Testosterone undecanoate (TU) substitution therapy.
  
  
  METHODS
  Two hundred and seven patients treated with TU (Nebido(®)) were genotyped by quantitative polymerase chain reaction for the UGT2B17 deletion polymorphism. All were given 1000 mg TU per injection at 0, 6, and 18 weeks. Blood samples were taken 2 and 6 weeks after the first and second injection, prior to the third injection, and after 2-3 years of treatment. We analyzed for the levels of T, luteinizing hormone (LH), sex-hormone-binding globulin, estradiol, prostate specific antigen, hematocrit, hemoglobin, and total cholesterol.
  
  
  RESULTS
  The UGT2B17 genotype frequency was: ins/ins: 42%, ins/del: 44%, and del/del: 14%. During the initial 18 weeks of TU treatment, large intra- and inter-individual variations in serum T levels were observed. Large peaks in T levels, ranging from 6.7 to 69.5 nmol/l, were noted 2 weeks after injections, regardless of the genotype. T levels did not differ between the three genotypes prior to the third injection, but the del/del group had significantly lower levels of LH. At follow-up after 2-3 years, the injection interval or daily T dosage was not dependent on the UGT2B17 genotype.
  
  
  CONCLUSIONS
  In conclusion, we found large intra- and inter-individual variations in serum T during standard TU treatment regimen in hypogonadal men. Only subtle differences in serum T and LH were noted according to UGT2B17 genotype, which however suggest that the UGT2B17 genotype exert modest influence on the pharmacokinetic profile of T after TU treatment.
authors.affiliation: Department of Growth and Reproduction, Faculty of Health and Medical Sciences, Rigshospitalet, University of Copenhagen , Copenhagen , Denmark.
authors.forename: Anne Kirstine
authors.initials: AK
authors.lastname: Bang
authors.forename: Niels
authors.initials: N
authors.lastname: Jørgensen
authors.forename: Ewa
authors.initials: E
authors.lastname: Rajpert-De Meyts
authors.forename: Anders
authors.initials: A
authors.lastname: Juul
keywords: UGT2B17; hypogonadism; testosterone; testosterone treatment; testosterone undecanoate
references.citation: Front Endocrinol (Lausanne). 2013 May 16;4:51
references.pmid: 23720652
references.citation: J Clin Endocrinol Metab. 2007 Dec;92(12):4878-82
references.pmid: 17698910
references.citation: Expert Opin Pharmacother. 2010 Aug;11(12):2095-106
references.pmid: 20642374
references.citation: Nutr J. 2012 Sep 07;11:67
references.pmid: 22958586
references.citation: Hum Reprod. 2002 Aug;17(8):2199-208
references.pmid: 12151459
references.citation: Eur J Clin Invest. 2013 Mar;43(3):248-55
references.pmid: 23294483
references.citation: J Clin Endocrinol Metab. 2011 Nov;96(11):3440-7
references.pmid: 21849521
references.citation: J Clin Endocrinol Metab. 2009 Mar;94(3):1005-11
references.pmid: 19088161
references.citation: Am J Hum Genet. 2008 Dec;83(6):663-74
references.pmid: 18992858
references.citation: J Clin Endocrinol Metab. 2006 Feb;91(2):687-93
references.pmid: 16332934
references.citation: J Clin Endocrinol Metab. 1999 Oct;84(10):3666-72
references.pmid: 10523012
references.citation: Trends Endocrinol Metab. 2003 Dec;14(10):473-9
references.pmid: 14643063
references.citation: Steroids. 2009 Nov;74(12):971-7
references.pmid: 19643121
references.citation: Aging Male. 2006 Dec;9(4):221-7
references.pmid: 17178558
references.citation: Clin Endocrinol (Oxf). 2008 Oct;69(4):642-7
references.pmid: 18394021
references.citation: Pharmacogenet Genomics. 2011 Jun;21(6):325-32
references.pmid: 21383644
references.citation: Clin Endocrinol (Oxf). 2006 Sep;65(3):275-81
references.pmid: 16918944
references.citation: J Clin Endocrinol Metab. 2008 Jul;93(7):2500-6
references.pmid: 18334593
references.citation: Steroids. 2012 May;77(6):691-5
references.pmid: 22429924
references.citation: Drug Metab Dispos. 2009 Feb;37(2):417-23
references.pmid: 19022937